Author(s): Michele Reni, MDa,b; Marina Macchini, MDa; Giulia Orsi, MDa; Letizia Procaccio, MDc; Giuseppe Malleo, MDd; Catia Carconi, MDa,b; Ilario Giovanni Rapposelli, MDe; Katia Bencardino, MDf; Prof Mario Scartozzi, MDg; Gianpaolo Balzano, MDh; Domenico Tamburrino, MDb,h; Barbara Merelli, MDi; Elisa Sperti, MDj; Giulio Belfiori, MDh; Nicole Liscia, MDa; Silvia Bozzarelli, MDk; Mariacristina Di Marco, MDl,m; Emiliano Tamburini, MDn; Prof Michele Milella, MDo; Sara Lonardi, MDc; Giorgio Ercolani, MDl,p; Michele Mazzola, MDq; Diego Palumbo, MDb,r; Valter Torri, MDs; Prof Massimo Falconi, MDb,h
BACKGROUND
Perioperative chemotherapy is a standard option for treatment of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC). This study aimed to assess the superiority of PAXG (cisplatin, nab-paclitaxel, capecitabine, and gemcitabine) over mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, and oxaliplatin) in this population.
METHODS
CASSANDRA is a randomised, open-label, 2 × 2 factorial phase 3 trial, involving 17 Italian academic hospitals. Eligible patients were aged 18–75 years with pathologically confirmed resectable or borderline resectable PDAC. Randomisation was performed by a central web-based system using R-code lists with a computerised algorithm. The design adopted a 1:1 randomisation, with a block stratification by centre and carbohydrate antigen 19-9. Participants were first randomly assigned PAXG (total daily capecitabine dose of 1250 mg/m2 in a 625 mg/m2 twice a day dosage and intravenous cisplatin 30 mg/m2, nab-paclitaxel 150 mg/m2, and gemcitabine 800 mg/m2 every 14 days) or mFOLFIRINOX (intravenous fluorouracil 2400 mg/m2, leucovorin 400 mg/m2, irinotecan 150 mg/m2, and oxaliplatin 85 mg/m2 every 14 days) for 4 months, followed by a second randomisation to 2 months of additional chemotherapy either before or after surgery. The primary endpoint was event-free survival (EFS) in the intention-to-treat population and the safety population included all patients who received at least one cycle of the assigned therapy. The results of the first randomisation are reported here. The trial, registered on ClinicalTrials.gov (NCT04793932) and EudraCT (2020-003080-26 and 2024-519031-42-00), completed accrual and reached the necessary events for first randomisation primary analysis but follow-up of overall survival is ongoing.
FINDINGS
Between Nov 3, 2020, and April 24, 2024, 132 eligible patients were assigned to PAXG and 128 to mFOLFIRINOX. In the PAXG group, the median age was 65 years (IQR 60–70), 68 (52%) of 132 patients were female, and 64 (48%) were male. In the mFOLFIRNOX group, the median age was 63 years (IQR 57–69), 62 (48%) of 128 patients were female, and 66 (52%) were male. All 260 patients received at least one assigned chemotherapy administration. PAXG prolonged the median EFS compared with mFOLFIRINOX (16·0 months [95% CI 12·4–19·8] vs 10·2 months [8·6–13·5]; hazard ratio 0·63 [0·47–0·84]; p=0·0018). At least one grade 3 or worse adverse event was observed in 87 (66%) of 132 patients in the PAXG group and in 78 (61%) of 128 patients in the mFOLFIRINOX group, including one fatal event.
INTERPRETATION
PAXG significantly improved EFS compared with mFOLFIRINOX in resectable or borderline resectable PDAC. Preopertive PAXG could be considered a standard option for resectable or borderline resectable PDAC. Accordingly, preoperative PAXG should be considered as the standard comparator group for future trials in this setting.
FUNDING
MyEverest and Codice Viola.
Author Affiliations
a Department of Medical Oncology, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; b Vita-Salute San Raffaele University, Milan, Italy; c Oncology 1 Unit, Veneto Institute of Oncology IOV—IRCCS, Padua, Italy; d Pancreatic Surgery Unit, Pancreas Institute, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy; e Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy; f Niguarda Cancer Center, Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; g Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy; h Division of Pancreatic and Transplant Surgery, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Hospital, Milan, Italy; i Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy; j SCDU Oncologia Medica, AO Ordine Mauriziano di Torino, Turin, Italy; k Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; l Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; m Medical Oncology Unit, IRCSS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; n Department of Oncology and Palliative Care, Cardinale Giovanni Panico Hospital, Tricase, Italy; o Section of Innovation Biomedicine—Oncology Area, Department of Engineering for Innovation Medicine, University of Verona, and Verona University and Hospital Trust, Verona, Italy; p Department of General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy; q Division of Minimally-Invasive Surgical Oncology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; r Department of Radiology, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; s Clinical Oncology Department, Mario Negri Institute—IRCCS, Milan, Italy
